{'fraction_non_alphanumeric': 0.046214355948869225, 'fraction_numerical': 0.02654867256637168, 'mean_word_length': 4.784090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Evaluation of the results of chemotherapy in squamous cell bronchial carcinoma].

Chemotherapy according to the MACC protocol (Methotrexate, Adriamycin, Cyclophosphamide, CCNU) was applied in 32 patients with squamous cell bronchial carcinoma. The following criteria were used for the evaluation of the effect of therapy: response to therapy (evaluation of decrease in tumor mass), duration of response and survival time. A positive response to therapy was achieved in 3 (9.4%) cases. In 22 (68.7%) the condition remained unchanged, while in 7 (21.9%) cases there came to a progression of the disease. Mean duration of survival was 15.1 +/- 8.2 months. More than a half of the patients lived for a year (59.4%), while 12.5% and 9.4% survived two and three years, respectively. By comparison of the results with findings from literature it seems that the application of chemotherapy in the combination of Cisplatin and Vindesin is more effective in the case of poorly differentiated squamous cell bronchial carcinoma.